Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

The United States’ shutdown of HIV/Aids funding may harm global Aids programmes irreparably, jeopardising millions of lives ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations., Hea ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are ...